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Introduction
A crisis of malignant hyperthermia is a
medical emergency, and must be
treated immediately with a coordinated,
multidisciplinary team response in order
to give the patient the highest chance
for a successful recovery (Dirksen, Van
Wicklin, Mashman, Neiderer, & Merritt,
2013). Malignant hyperthermia is
defined by Bandschapp & Girard
(2012), as “a disturbance of the skeletal
muscle calcium homeostasis, triggered
by volatile anaesthetics and
depolarizing muscle relaxants.” Once a
vulnerable patient is exposed to one of
these triggering agents, a pathologic
hypermetabolic response ensues, and
the patient has a rapid increase in
oxygen consumption and expired
carbon dioxide, hyperthermia, acidosis,
muscle rigidity, and hyperkalemia
(Bandschapp & Girard, 2012).
The event of malignant hyperthermia
is very rare, but can easily progress to
a life-threatening situation (Cain, Riess,
Gettrust, & Novalija, 2014). Many
clinicians are unprepared to manage
and treat the event because of its rarity
and the use of low-frequency, high risk
skill set (Cain, Riess, Gettrust, &
Novalija, 2014). Dirksen, Van Wicklin,
Mashman, Neiderer, & Merritt (2013),
claim that malignant hyperthermia
occurs in approximately 1:3,000-50,000
procedures in which general
anesthetics are used.

Presentation of Case

Although the prevalence rate is low
there is a good chance an anesthesia
clinician will experience a malignant
hyperthermia crisis at least once in
their career and they must be aware of
how to handle the situation. That is
why I picked this rare topic. I am in the
Nurse Anesthesia program, and
providing information about this crisis
can spread awareness about a
situation that could directly affect my
colleagues’ or my own career.
The condition was termed in 1960,
by Denborough and Lovell who
described the disorder in a family with
this autosomal dominant mode of
inheritance (Bandschapp & Girard,
2012). Years later in the 1970’s
mortality rates for the hyperthermia
crisis were still over 80%, and after
years of research the pathogenesis of
the complication was discovered,
along with the medical treatment in
dantrolene (Bandschapp & Girard,
2012).
Currently, mortality rates have
decreased to less than 5% because of
the symptoms being immediately
recognized and treated by anesthesia
clinicians (Bandschapp & Girard,
2012). Malignant hyperthermia is still a
very dangerous state, yet very
treatable under the proper clinician
education.

(Muldoon, 2014)

A 34 y.o. man was admitted to the
hospital for a cholecystectomy. On
preop assessment the CRNA found
no previous surgeries and a family
history of anesthetic complications,
but the patient could not tell what
these issues were. Surgery went well
with removal of the gallbladder,
successful anesthetic reversal, and
no apparent complications. After
surgery the patient was stable with
HR, 75 bpm, BP, 127/82, RR, 16/min,
O2sat, 100%, temp., 36.9 C. Upon
admission to the PACU, patient’s HR
increases to 91 bpm, and RR, 21/min,
and the nurse gives the patient 3 mg
of Morphine IVP for pain and
increases his oxygen delivery to 4 L
NC. The nurse then continues to see
increase in HR, RR, BP, and temp.
After giving the patient another 3mg
of Morphine IVP, and increasing his
oxygen to 5L NC, the nurse calls the
CRNA and surgeon to report changes
in patient’s condition. After this, the
patient reports muscle rigidity of the
trunk, displays ventricular ectopy, and
vital signs are now as follows: HR:
127 bpm, BP: 167/101 mm Hg, RR:
31/min, O2sat: 89%, and body temp:
39.5 C. The CRNA, now at bedside,
quickly makes the diagnosis of
malignant hyperthermia and
administers 2.5mg/kg of dantrolene
IVP and 2 mEq/kg of bicarbonate and
reintubated the patient. A cooling
blanket is then applied to the patient

and an ABG and labs are drawn that show: pH, 7.21; Pco2, 75 mmHg;
Po2, 85 mmHg; potassium, 7.2 mEq/L. The patient is then given 10
units of regular insulin IVP, followed by 50 ml of 50% dextrose in water
IV, and 10 mg/kg of calcium chloride. The patient is then transferred to
the ICU unit (Anderson-Pompa, Foster, Parker, Wilks & Cheek, 2009).
This patient displays the many signs and symptoms of the post
operative emergency, malignant hypothermia (MH). This is a condition
that develops rapidly and must be treated immediately. This genetic
skeletal muscle disorder does not always happen immediately. In
some cases like this example, the signs and symptoms can occur after
surgery in the recovery period (Cain, Riess, Gettrust, & Novalija,
2014). The condition results in the body developing into a
hypermetabolic state with tachycardia, hyperpyrexia, muscle
contractions, and changes in electrolyte and acid-base balances
(Johns, Stoudt, Scholtis, & Gavel, 2012). More specific clinical signs of
MH included: a rise in end-tidal CO2 and lactic acid production leading
to a respiratory and metabolic acidosis, muscle spasm/rigidity,
especially of the masseter muscle and truncal area, hyperthermia of
above 39º C, myoglobinuria and eventually renal failure,
hyperkalemia, tachycardia/tachypnea, and cardiac arrhythmias/arrests
(Dirksen, Van Wicklin, Mashman, Neiderer, & Merritt, 2013). These
symptoms must be recognized quickly and there must be an
emergency care plan in place to treat patients displaying these
symptoms.

Implications

Pathophysiology and Significance
The underlying pathophysiology behind malignant hyperthermia begins with
the excitation-contraction coupling mechanism where “the muscle action
potential is propagated along the sarcolemmal membrane into the transverse
tubule, where the dihydropyridine receptors (DHP receptor) sense the action
potential voltage change and open up” (Bandschapp & Girard, 2012). The
opening of the DHP receptors then activates the ryanodine recepors to open,
which allows calcium to be released from the Sarcoplasmic reticulum of the
muscle cells and cause muscle contraction (Bandschapp & Girard, 2012). The
muscle contraction then relaxes as calcium is actively pumped back into the
sarcoplasmic reticulum by the ATP-dependent calcium pump (Revello, 2012).
Patients that are susceptible to MH have an autosomal dominant disorder in
which they have a defect in the ryanodine receptor type 1 (RYR1) gene (Dirksen,
Van Wicklin, Mashman, Neiderer, & Merritt, 2013). By pairing this abnormal
ryanodine receptor gene with the presence of a triggering agent like anesthetic
gasses (halothane, isoflurane, sevoflurane, desflurane, or enflurane) either
alone or in combination with a depolarizing muscle relaxant (succcinylcholine),
an uncontrolled calcium release from the sarcoplasmic reticulum will result as an
effect of the triggering agent causing the RYR1 to remain open (Dirksen, Van
Wicklin, Mashman, Neiderer, & Merritt, 2013). This calcium starts the actinmyosin troponin interaction which makes the muscle contract by shortening the
muscle fibers (Dirksen, Van Wicklin, Mashman, Neiderer, & Merritt, 2013). This
uncontrolled calcium release overwhelms the compensatory mechanism
(calcium pump) within the cell and cause a sustained state of muscle
contraction, which causes the hypermetabolic MH response (Dirksen, Van
Wicklin, Mashman, Neiderer, & Merritt, 2013). Early on the muscle cells attempt
to restore homeostasis through aerobic and anaerobic metabolism, however it is
overpowered by the excessive amount of calcium in the myoplasm, and reaches
the threshold levels for myofibrillar contraction (Revello, 2012).

(Revello, 2012)

This process is significant in that it rapidly depletes adenosine triphosphate
(ATP) and increases glucose metabolism, oxygen consumption, carbon dioxide
production, and heat production; as well as increases lactate production and
worsens acidosis (Revello, 2012). As ATP stores become exhausted, the
plasma membrane integrity lessens causing rhabdomyolysis and the leakage of
myoglobin, CK, and electrolytes like potassium, phosphate, and magnesium into
the circulation (Revello, 2012). This damage can cause skeletal muscle damage,
renal failure, and cardiac arrhythmias or arrest (Dirksen, Van Wicklin, Mashman,
Neiderer, & Merritt, 2013).

Implications must be taken especially by
CRNA’s to monitor and be prepared for
a MH crisis. Although a classic sign of
MH is pyrexia, an increase in
temperature usually occurs later than
other signs (Bandschapp & Girard,
2012). One of the first signs of MH is the
continual occurrence of increased
carbon dioxide despite increases in
minute ventilation (Bandschapp &
Girard, 2012). If this is noticed along with
tachycardia, muscle rigidity, possible
hyperthermia, diffuse perspiration,
(Shrestha, 2013)
acidosis, and hyperkalemia, the CRNA
or Anesthesiologist must be clued to the
diagnosis of MH, and act immediately.
Once MH is suspected, all triggering agents should be discontinued including
the anesthetic gas, and sedation should be changed to propofol (Bandschapp &
Girard, 2012). Then help should be called, and a preplanned MH multidisciplinary
team/plan should be activated and personnel should follow preset MH policies and
guidelines (Dirksen, Van Wicklin, Mashman, Neiderer, & Merritt, 2013). The CRNA
should then hyperventilate the patient with high fresh gas flow (>10 L/min or 1.0
FiO2), and then treat the patient with 2.5mg/kg bolus of dantrolene (Bandschapp &
Girard, 2012).
Dantorlene is a specific ryanodine receptor
antagonist, and inhibits the increased calcium
release form the sarcoplasmic reticulum, which
is why it is the primary drug to treat MH
(Bandschapp & Girard, 2012). The 2.5mg/kg
bolus can be repeated up to 4 times until the
MH signs and acidosis subside, and in some
cases may require more than 10mg/kg
(Bandschapp & Girard, 2012). The patient then
(JHP Pharmaceuticals, LLC, 2014)
must be packed in ice to attempt to keep the
patient’s temperature below 38.5 ºC. CRNAs must also regularly draw ABGs, and
blood and urine labs, to check acid-base status, electrolytes, coagulation profile,
creatinine, CK, and myoglobin (Bandschapp & Girard, 2012). If acidosis worsens or
serum potassium climbs, an additional bolus of dantrolene should be given
(Bandschapp & Girard, 2012).
CRNAs must also be attentive and
monitor and treat other conditions
caused by MH, like disseminated
intravascular coagulation, kidney
damage form the myoglobin in the blood,
and rhabdomyolysis associated with
electrolyte imbalances (Bandschapp &
Girard, 2012). They may need to give
fluids and diuretics to help clear
myoglobin in the kidneys, or correct
electrolyte imbalances, especially
hyperkalemia. Once the condition is
under control the patient needs to be
transported to the intensive care unit for
36-48 hours to monitor for possible
reoccurring symptoms, and 1 mg/kg of
dantrolene should be continued every 48 hours as indicated by lab values and
clinical parameters (Bandschapp &
Girard, 2012).

Conclusion

Malignant Hyperthermia is a
medical emergency, and although rare,
every person involved in the OR team
must be prepared to act quickly and
accurately to give the patient the best
chance for survival. The only testing for
MH includes a muscle biopsy or
molecular genetic testing, which are too
invasive for a preoperative screen
(Bandschapp & Girard, 2012).
Therefore, a thorough surgical and
medical history must be done on the
patient to check for possible MH
complications that have occurred in the
family. Perioperative personnel,
especially CRNAs, must be properly
educated to quickly and appropriately
recognize, treat, and manage a patient
in a malignant hyperthermia crisis.
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